MSN Seeks Supreme Court Review in Challenge of Novartis Patent

MSN Pharmaceuticals Inc. urged the US Supreme Court to chop down a line of Federal Circuit opinions that the generics maker said provides too much protection to overly broad drug patents, including one for the blockbuster drug Entresto.

The company is challenging the appeals court’s rejection of MSN’s argument that a Novartis Pharmaceuticals Corp. patent filed in 2002 and covering a combination of the drugs valsartan and sacubitril to treat heart failure is invalid. MSN says the patent’s claims were read broadly for infringement purposes to cover its “complexed” drug that merged the compounds together as a single entity but ...